Standard BioTools Inc.

NasdaqGM:SLGC Stock Report

Market Cap: US$396.2m

Standard BioTools Dividend

Dividend criteria checks 0/6

Standard BioTools does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield0.4%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.69
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17
SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02
Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

SomaLogic appoints former Foundation Medicine chief as executive chair

Oct 17

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

Jul 26

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Jun 06
We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Apr 12

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

Mar 09
Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Dec 28
We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SLGC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLGC's dividend payments have been increasing.


Dividend Yield vs Market

Standard BioTools Dividend Yield vs Market
How does SLGC dividend yield compare to the market?
SegmentDividend Yield
Company (SLGC)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.8%
Industry Average (Life Sciences)0.4%
Analyst forecast in 3 Years (SLGC)n/a

Notable Dividend: Unable to evaluate SLGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SLGC's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLGC has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.